Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP430022.RA4OvT6WcHFsgenjpr8FnPWCMnXuRJSOiyDC592QaEhgk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP430022.RA4OvT6WcHFsgenjpr8FnPWCMnXuRJSOiyDC592QaEhgk130_assertion type Assertion NP430022.RA4OvT6WcHFsgenjpr8FnPWCMnXuRJSOiyDC592QaEhgk130_head.
- NP430022.RA4OvT6WcHFsgenjpr8FnPWCMnXuRJSOiyDC592QaEhgk130_assertion description "[Response rates (RRs) to and progression-free survival (PFS) after taxane chemotherapy of 35 BRCA1-associated and 13 BRCA2-associated metastatic breast cancer patients were compared with those outcomes in 95 matched (1:2) sporadic patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430022.RA4OvT6WcHFsgenjpr8FnPWCMnXuRJSOiyDC592QaEhgk130_provenance.
- NP430022.RA4OvT6WcHFsgenjpr8FnPWCMnXuRJSOiyDC592QaEhgk130_assertion evidence source_evidence_literature NP430022.RA4OvT6WcHFsgenjpr8FnPWCMnXuRJSOiyDC592QaEhgk130_provenance.
- NP430022.RA4OvT6WcHFsgenjpr8FnPWCMnXuRJSOiyDC592QaEhgk130_assertion SIO_000772 21761396 NP430022.RA4OvT6WcHFsgenjpr8FnPWCMnXuRJSOiyDC592QaEhgk130_provenance.
- NP430022.RA4OvT6WcHFsgenjpr8FnPWCMnXuRJSOiyDC592QaEhgk130_assertion wasDerivedFrom befree-20140225 NP430022.RA4OvT6WcHFsgenjpr8FnPWCMnXuRJSOiyDC592QaEhgk130_provenance.
- NP430022.RA4OvT6WcHFsgenjpr8FnPWCMnXuRJSOiyDC592QaEhgk130_assertion wasGeneratedBy ECO_0000203 NP430022.RA4OvT6WcHFsgenjpr8FnPWCMnXuRJSOiyDC592QaEhgk130_provenance.